NEWS HIGHLIGHTSMedia Articles Related to Ganirelix
International Event At Queen's Focuses On Male Infertility
Source: Conferences News From Medical News Today [2009.11.19]
Male infertility and tackling falling birth rates across Europe will be among the topics addressed at this year's British Andrology Society's annual conference at Queen's University in Belfast. World leaders in the field of andrology - the study of male reproduction - will meet at Queen's this week (Thursday and Friday) to discuss the latest developments in the field of fertility including the potential to create artificial sperm from stem cells.
European Urology: Male Factor Infertility Associated With Comorbidities
Source: Fertility News From Medical News Today [2009.11.11]
The December issue of European Urology, the official journal of the European Association of Urology, features an article entitled 'Are Infertile Men Less Healthy than Fertile Men? Results of a Prospective Case-Control Survey' by Dr. Andrea Salonia et al. The conclusion is that male factor infertility is associated with a number of medical comorbidities, as objectively scored with the hospital-based Charlson Comorbidity Index. Dr.
Male Infertility Tied to Testicular Cancer Risk
Source: MedicineNet Testicular Cancer Specialty [2009.02.24]
Title: Male Infertility Tied to Testicular Cancer Risk
Category: Health News
Created: 2/24/2009 2:00:00 AM
Last Editorial Review: 2/24/2009
Study: Infertility Treatments No Help
Source: MedicineNet Polycystic Ovary Specialty [2008.08.08]
Title: Study: Infertility Treatments No Help
Category: Health News
Created: 8/8/2008
Last Editorial Review: 8/8/2008
Infertility
Source: MedicineNet Endometrial Biopsy Specialty [2007.02.07]
Title: Infertility
Category: Diseases and Conditions
Created: 11/17/2004
Last Editorial Review: 2/7/2007
Published Studies Related to Ganirelix
Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. [2006.03]
BACKGROUND: This study was designed to assess whether the use of ganirelix in women undergoing stimulated IUI could prevent the occurrence of premature LH rises and luteinization (LH+progesterone rises)... CONCLUSIONS: Treatment with ganirelix effectively prevents premature LH rises, luteinization in subjects undergoing stimulated IUI. Low-dose rFSH regimen combined with a GnRH antagonist may be an alternative treatment option for subjects with previous proven luteinization or in subjects who would otherwise require insemination when staff are not working.
LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome. [2005.12]
Elevated LH concentration is a common feature in polycystic ovary syndrome (PCOS). This study was designed to establish whether elevated LH levels in PCOS might be suppressed to normal range values by the administration of different low doses of GnRH antagonist, which subsequently might reverse the anovulatory status of these patients...
Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. [2005.07]
OBJECTIVE: To compare the safety and efficacy of single-dose cetrorelix acetate (3 mg) and daily ganirelix acetate (0.25 mg) in the inhibition of premature LH surge in women undergoing cycle-programmed ovarian stimulation before Assisted Reproductive Technology (ART).CONCLUSION(S): Cetrorelix and ganirelix effectively prevented LH surges in oral contraceptive (OC) pill-programmed, flexible protocols, with similar safety profiles and PRs; however, cetrorelix required significantly fewer injections, increasing patient convenience.
A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. [2005.05]
Forty-eight patients who met the criteria of poor response during prior gonadotropin stimulation were enrolled in a randomized prospective study comparing a gonadotropin-releasing hormone (GnRH) antagonist protocol, using ganirelix acetate, with a microdose GnRH agonist protocol for in vitro fertilization-embryo transfer (IVF-ET).
A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy. [2004.08]
OBJECTIVE: The purpose of this study was to determine if use of a Gonadotropin releasing hormone (GnRH) antagonist, Ganirelix (Antagon), can improve pregnancy rates during superovulation with recombinant follicle-stimulating hormone (rFSH) followed by intrauterine insemination (IUI)... CONCLUSION: Superovulation/IUI cycles using Ganirelix produce similar pregnancy rates when compared with cycles not using a GnRH antagonist, although there is a trend towards better pregnancy rates in cycles with Ganirelix.
Clinical Trials Related to Ganirelix
A Comparison of the Microdose Leuprolide Protocol vs. Luteal Phase Ganirelix Protocol in Women Who Are or Who Are Predicted to be Low Responders [Recruiting]
Patients who have undergone in vitro fertilization (IVF) and produced four or less follicles
or had four or less oocytes (eggs) retrieved are often referred to as poor responders. We
will refer to these patients from this point forward as "low responders" to avoid using a
potentially offensive label. We are currently using 2 different IVF medication protocols in
our practice to treat low responder patients with infertility: the "Microdose Leuprolide"
protocol and the "Luteal Phase Ganirelix" protocol. We would like to conduct a
randomized-controlled trial and randomize patients to one treatment group or the other to
determine which medication protocol is more effective in treating infertility in this group
of patients.
Antagonist/Letrozole in Poor Responders [Recruiting]
Failure to respond to controlled ovarian hyperstimulation (COH) is still a major
concern in assisted reproduction and there is no consensus on the ovarian
stimulation choice regime for poor responders.
Aim: To evaluate and compare the efficacy of a microdose GnRH agonist flare
(MF) and a GnRH antagonist/letrozole (A/L) protocols in poor responders undergoing
in vitro fertilization (IVF).
Methods: One hundred eighty poor responder patients will be randomized to an
ovarian stimulation protocol with either a MF or a letrozole and high dose
FSH/hMG and flexible GnRH antagonist protocol.
Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women [Recruiting]
The purpose of this study is to find out why women's arteries stiffen as they go through
menopause, and how this is affected by estrogen loss. We believe that arteries stiffen with
the loss of estrogen because of "oxidative stress," the production of molecules that can
damage cells and tissues in the body, and because the arteries lose their ability to expand,
or dilate.
The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration [Recruiting]
Women are at greater risk for exercise-induced hyponatremia (low blood sodium concentration)
and this risk has been attributed to their lower body weight and size, excess water
ingestion and longer racing times relative to men. While these factors contribute to the
greater incidence of hyponatremia in women, it is likely that their greater levels of
estradiol in plasma and/or tissue also play a role in increasing the risk of hyponatremia in
women. More importantly, estradiol may also leave women more susceptible to the extreme
consequences of hyponatremia (i. e. brain damage, death). Hyponatremia is generally
attributed to inappropriately elevated levels of the hormone arginine vasopressin (AVP).
AVP is the most important hormone controlling water retention in the kidney. Earlier studies
in our laboratory have demonstrated that estradiol lowers the threshold for thirst sensation
and AVP release during exercise. The purpose of these studies is to test the hypotheses that
in women with a history of hyponatremia, estradiol lowers the thresholds for thirst and AVP
release, leading to greater fluid retention, lower blood sodium concentration during
endurance exercise in the heat. However, we further hypothesize that progesterone
administration along with estradiol administration will attenuate the effect of estradiol on
the regulation of thirst and AVP, normalize fluid retention, and serum sodium concentration
during endurance exercise in the heat. In women without a history of hyponatremia, we
expect that estradiol administration will lower the thresholds for thirst and AVP release,
but will not increase fluid retention or reduce blood sodium concentration during endurance
exercise in the heat. We hypothesize that progesterone administration along with estradiol
administration will attenuate the effect of estradiol on thirst and AVP, but have no effect
on fluid retention or serum sodium concentration during endurance exercise in the heat. To
test these hypotheses, women will perform endurance exercise in the heat under three
hormonal conditions: 1) during Gonadotropin-releasing hormone (GnRH) antagonist
alone--which will suppress estradiol and progesterone; 2) during GnRH antagonist+estradiol;
and 3) during GnRH antagonist+estradiol+ progesterone. During exercise, fluid will be
replaced with either water or a carbohydrate-electrolyte beverage (random assignment).
Compromised Microcirculation in Women With Polycystic Ovary Syndrome [Recruiting]
The scientific aims of the study are to determine how peripheral microcirculatory
responsiveness is altered in obese women with Polycystic Ovary Syndrome (PCOS) during local
heating and to determine the mechanism for testosterone effects on peripheral
microcirculatory responsiveness in women with PCOS.
|
